<DOC>
	<DOCNO>NCT01571817</DOCNO>
	<brief_summary>The overall objective pilot project evaluate safety efficacy gastric submucosal space novel site clinical islet transplantation . The site several physiologic attribute may improve outcome islet transplantation compare conventional intraportal transplant site .</brief_summary>
	<brief_title>Pancreatic Islet Transplantation Into Gastric Submucosa</brief_title>
	<detailed_description />
	<criteria>Key 1 . Primary islet allotransplant 2 . Type I diabetes mellitus minimum 5 year 3 . One follow sign symptom despite intensive effort make close cooperation diabetic care team : Metabolic lability/instability characterize hypoglycemia ketoacidosis ( &gt; 2 hospital admission previous year ) , erratic glucose profile ( MAGE &gt; 120 mg/dL ) , disruption lifestyle danger life , self others Reduced awareness hypoglycemia &gt; 1 episode last 1.5 year severe hypoglycemia Persistently poor glucose control ( define HgbA1c &gt; 10 % end six month Intensive management effort diabetes care team ) Progressive secondary complication define ( ) new proliferative retinopathy clinically significant macular edema therapy photocoagulation last year ; ( ii ) symptomatic autonomic neuropathy ( defined postural hypotension neuropathic bladder ) 4 . Age 18 old 5 . Patients renal transplant must receive transplant least 3 month previously must stable renal function ( see exclusion criterion ) 6 . Must able give write informed consent Key 1 . Lymphopenia ( &lt; 1000/µL ) leukopenia ( &lt; 3000 total leukocytes/µL ) 2 . Presence panelreactive antiHLA antibody &gt; 20 % 3 . Positive lymphocytotoxic crossmatch use donor lymphocyte serum 4 . Evidence acute EBV infection ( IgM &gt; IgG ) OR serologic evidence previous exposure EBV ( IgG &gt; IgM ) 5 . Calculated measure GFR &lt; 50 ml/min/m2 patient without renal transplant . 6 . Calculated measure GFR &lt; 40 ml/min/m2 patient renal transplant . 7 . Portal hypertension history significant liver disease 8 . History malignancy within 10 year ( except treat basal squamous cell CA skin ) 9 . Active peptic ulcer disease gastric mucosal abnormality identify screen endoscopy 10 . Severe unremitting diarrhea GI disorder potentially interfere ability absorb oral medication 11 . Untreated proliferative retinopathy 12 . Pregnancy breastfeed 13 . Female subject postmenopausal surgically sterile sexually active use acceptable method contraception 14 . Active infection 15 . Serologic evidence infection HIV , HbsAg HCV Ab positive 16 . Major ongoing psychiatric illness 17 . Ongoing substance abuse , drug alcohol ; recent history noncompliance 18 . Any condition opinion Principal Investigator allow safe participation study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Insulin Dependent</keyword>
</DOC>